A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation.

BACKGROUND Exogenous pulmonary surfactants are administered into the trachea either to prevent respiratory distress syndrome in premature infants or to treat it. In a randomized, multicenter trial, we compared the results of surfactant therapy initiated as prophylaxis with the results of rescue therapy with surfactant. METHODS Before birth, 479 infants with an estimated gestational age of less than 30 weeks were randomly assigned to receive surfactant as prophylaxis (n = 235) or rescue therapy (n = 244). The infants in the prophylaxis group received a 90-mg intratracheal dose of an exogenous calf-lung surfactant extract at the time of delivery, whereas the infants in the rescue-therapy group received 90 mg of the surfactant several hours after delivery if the fractional inspiratory oxygen concentration was at least 0.40 or if the mean airway pressure was at least 0.686 kPa (7 cm of water), or both. Infants in both groups received additional doses of surfactant at intervals of 12 to 24 hours if these criteria were met. RESULTS The proportion of infants surviving until discharge to their homes was significantly higher in the prophylaxis group than in the rescue-therapy group (88 vs. 80 percent, P = 0.028). This difference was due primarily to the longer survival of very premature infants (less than or equal to 26 weeks' gestation) in the prophylaxis group than in the rescue-therapy group (75 vs. 54 percent, P = 0.006). According to proportional-hazards regression analysis, the distribution of survival times was better for all infants in the prophylaxis group (P = 0.007) and for the subgroup of infants in the prophylaxis group who were delivered at 26 weeks' gestation or earlier (P = 0.0048). Infants in the prophylaxis group who were delivered at 26 weeks' gestation or earlier had a lower incidence of pneumothorax than similar infants in the rescue-therapy group (7 vs. 18 percent, P = 0.03). CONCLUSIONS We found a significant advantage to the administration of the initial dose of surfactant as prophylaxis rather than as rescue therapy in very premature infants.

[1]  R. E. Hoekstra,et al.  Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group. , 1990, Pediatrics.

[2]  D. Phelps,et al.  Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. , 1988, Pediatrics.

[3]  R. Bhat,et al.  Early and late surfactant treatments in baboon model of hyaline membrane disease. , 1988, Pediatrics.

[4]  H. Halliday,et al.  Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome. , 1988, Archives of disease in childhood.

[5]  R. Notter,et al.  Lung surfactants for replacement therapy: biochemical, biophysical, and clinical aspects. , 1987, Clinics in perinatology.

[6]  H. Kraemer,et al.  Use of physical and neurologic observations in assessment of gestational age in low birth weight infants. , 1987, The Journal of pediatrics.

[7]  R. Bhat,et al.  DOUBLE-BLIND CONTROLLED TRIAL OF SINGLE-DOSE TREATMENT WITH BOVINE SURFACTANT IN SEVERE HYALINE MEMBRANE DISEASE , 1987, The Lancet.

[8]  A. Feinstein,et al.  Clinical Epidemiology: The Architecture of Clinical Research. , 1987 .

[9]  J. Gitlin,et al.  Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. , 1987, Pediatrics.

[10]  S. Hurd,et al.  Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. , 1987, Pediatrics.

[11]  K. Benirschke,et al.  Prophylactic treatment of very premature infants with human surfactant. , 1986, The New England journal of medicine.

[12]  R. Notter,et al.  Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. , 1985, Pediatrics.

[13]  R. Notter,et al.  Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. , 1985, Pediatrics.

[14]  G. Enhorning,et al.  Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. , 1985, Pediatrics.

[15]  L Gluck,et al.  Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. , 1985, The Journal of pediatrics.

[16]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[17]  H. Morgenstern,et al.  Epidemiologic Research: Principles and Quantitative Methods. , 1983 .

[18]  L. Gluck,et al.  Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. , 1983, Pediatrics.

[19]  L. Papile,et al.  Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. , 1978, The Journal of pediatrics.

[20]  H. Ahrens,et al.  Brownlee, K. A.: Statistical Theory and Methodology in Science and Engineering. John Wiley & Sons, New York 1965, 590 S., 70 Abb., Tafelanhang , 1968 .